Taysha Gene Therapies Financial Statements
NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Taysha Gene Therapies revenue and earnings
In fiscal 2025, Taysha Gene Therapies generated $9.8 million in revenue, up 17.3% from fiscal 2024. Taysha Gene Therapies reported a net loss of $109.0 million, compared with a loss of $89.3 million a year earlier. Operating margin was -1130.6%.
Diluted earnings per share came in at -$0.34.
Summary generated from market data by MetaCap's automated system. Methodology
Taysha Gene Therapies income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Revenue | 9.77M | 8.33M | 15.45M | 2.50M | — | — |
| Revenue growth (YoY) | +17.28% | -46.07% | +517.55% | — | — | — |
| Operating Expenses | 120.27M | 99.79M | 87.89M | 164.95M | 173.27M | 43.00M |
| Research & Development | 86.40M | 66.00M | 56.78M | 91.17M | 131.94M | 31.89M |
| Operating Income | -110.50M | -91.46M | -72.44M | -162.45M | -173.27M | -43.00M |
| Interest Expense | 63.00K | 102.00K | 5.00M | 3.80M | 1.43M | 28.00K |
| Other Income (Expense) | 1.50M | 2.16M | -39.13M | -3.57M | -1.26M | -17.01M |
| Income Tax | 0 | 0 | 0 | 0 | — | 0 |
| Net Income | -109.00M | -89.30M | -111.57M | -166.01M | -174.52M | -60.01M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| EPS (Basic) | -0.34 | -0.36 | -0.96 | -3.78 | -4.64 | -3.40 |
| EPS (Diluted) | -0.34 | -0.36 | -0.96 | -3.78 | -4.64 | -3.40 |
| Shares Outstanding (Basic) | 319.71M | 250.13M | 116.12M | 43.95M | 37.65M | 17.67M |
| Shares Outstanding (Diluted) | 319.71M | 250.13M | 116.12M | 43.95M | 37.65M | 17.67M |
| EBITDA | -109.35M | -90.21M | -71.07M | -161.28M | -172.78M | -42.99M |
| Operating Margin | -1130.65% | -1097.55% | -468.83% | -6492.69% | — | — |
| Net Margin | -1115.27% | -1071.62% | -722.06% | -6635.25% | — | — |
This table shows 6 annual periods of Taysha Gene Therapies's income statement, from FY 2025 back to FY 2020, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow TSHA's reporting calendar. What is a income statement?